TLR3 Expression is a Potential Prognosis Biomarker and Shapes the Immune-Active Tumor Microenvironment in Esophageal Squamous Cell Carcinoma

References

• Li J, Xu J, Zheng Y, et al. Esophageal cancer: epidemiology, risk factors and screening. Chin J Cancer Res. 2021;33(5):535–547. doi:10.21147/j.issn.1000-9604.2021.05.01
   PubMed Web of Science ®Google Scholar
• Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360–373. doi:10.1053/j.gastro.2017.08.023
   PubMed Web of Science ®Google Scholar
• Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783–791. doi:10.1097/cm9.0000000000001474
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• He Z, Liu Z, Liu M, et al. Efficacy of endoscopic screening for esophageal cancer in China (ESECC): design and preliminary results of a population-based randomised controlled trial. Gut. 2019;68(2):198–206. doi:10.1136/gutjnl-2017-315520
   PubMed Web of Science ®Google Scholar
• Huang L, Xu H, Peng G. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy. Cell Mol Immunol. 2018;15(5):428–437. doi:10.1038/cmi.2018.4
   PubMed Web of Science ®Google Scholar
• Dajon M, Iribarren K, Cremer I. Toll-like receptor stimulation in cancer: a pro- and anti-tumor double-edged sword. Immunobiology. 2017;222(1):89–100. doi:10.1016/j.imbio.2016.06.009
   PubMed Web of Science ®Google Scholar
• Bonnin M, Fares N, Testoni B, et al. Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis. J Hepatol. 2019;71(4):763–772. doi:10.1016/j.jhep.2019.05.031
   PubMed Web of Science ®Google Scholar
• Chuang HC, Chou MH, Chien CY, Chuang JH, Liu YL. Triggering TLR3 pathway promotes tumor growth and cisplatin resistance in head and neck cancer cells. Oral Oncol. 2018;86:141–149. doi:10.1016/j.oraloncology.2018.09.015
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801. doi:10.1016/j.cell.2006.02.015
   PubMed Web of Science ®Google Scholar
• Muresan XM, Bouchal J, Culig Z, Souček K. Toll-like receptor 3 in solid cancer and therapy resistance. Cancers (Basel). 2020;12(11):3227. doi:10.3390/cancers12113227
   PubMed Web of Science ®Google Scholar
• Smith M, García-Martínez E, Pitter MR, et al. Trial watch: toll-like receptor agonists in cancer immunotherapy. Oncoimmunology. 2018;7(12):e1526250. doi:10.1080/2162402x.2018.1526250
   PubMed Web of Science ®Google Scholar
• Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology. 2013;2(8):e25961. doi:10.4161/onci.25961
   PubMed Web of Science ®Google Scholar
• Jin JO, Yu Q. Systemic administration of TLR3 agonist induces IL-7 expression and IL-7-dependent CXCR3 ligand production in the lung. J Leukoc Biol. 2013;93(3):413–425. doi:10.1189/jlb.0712360
   PubMed Web of Science ®Google Scholar
• Chang SC, Zhang BX, Su EC, et al. Hiltonol cocktail kills lung cancer cells by activating cancer-suppressors, PKR/ OAS,and restraining the tumor microenvironment. Int J Mol Sci. 2021;22:4. doi:10.3390/ijms22041626
   Web of Science ®Google Scholar
• Ishikawa T, Kageyama S, Miyahara Y, et al. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. Cancer Immunol Immunother. 2021;70(11):3081–3091. doi:10.1007/s00262-021-02892-w
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437. doi:10.1038/nm.3394
   PubMed Web of Science ®Google Scholar
• Zheng X, Song X, Shao Y, et al. Prognostic role of tumor-infiltrating lymphocytes in esophagus cancer: a meta-analysis. Cell Physiol Biochem. 2018;45(2):720–732. doi:10.1159/000487164
   PubMedGoogle Scholar
• King RJ, Qiu F, Yu F, Singh PK. Metabolic and immunological subtypes of esophageal cancer reveal potential therapeutic opportunities. Front Cell Dev Biol. 2021;9:667852. doi:10.3389/fcell.2021.667852
   PubMed Web of Science ®Google Scholar
• Baba Y, Yagi T, Kosumi K, et al. Morphological lymphocytic reaction, patient prognosis and PD-1 expression after surgical resection for oesophageal cancer. Br J Surg. 2019;106(10):1352–1361. doi:10.1002/bjs.11301
   PubMed Web of Science ®Google Scholar
• Shigeoka M, Urakawa N, Nakamura T, et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci. 2013;104(8):1112–1119. doi:10.1111/cas.12188
   PubMed Web of Science ®Google Scholar
• Lim KS, Mimura K, Kua LF, Shiraishi K, Kono K. Implication of highly cytotoxic natural killer cells for esophageal squamous cell carcinoma treatment. J Immunother. 2018;41(6):261–273. doi:10.1097/cji.0000000000000227
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu W, Hu B, et al. Prognostic significance of tumor-infiltrating natural killer cells in solid tumors: a systematic review and meta-analysis. Front Immunol. 2020;11:1242. doi:10.3389/fimmu.2020.01242
   PubMed Web of Science ®Google Scholar
• Sheyhidin I, Nabi G, Hasim A, et al. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World j Gastroenterol. 2011;17(32):3745–3751. doi:10.3748/wjg.v17.i32.3745
   PubMed Web of Science ®Google Scholar
• Sato Y, Motoyama S, Wakita A, et al. TLR3 expression status predicts prognosis in patients with advanced Thoracic esophageal squamous cell carcinoma after esophagectomy. Am J Surg. 2018;216(2):319–325. doi:10.1016/j.amjsurg.2018.01.038
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang M, Ying S, et al. Genetic alterations in esophageal tissues from squamous dysplasia to carcinoma. Gastroenterology. 2017;153(1):166–177. doi:10.1053/j.gastro.2017.03.033
   PubMed Web of Science ®Google Scholar
• Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. HistoPathology. 2020;76(2):182–188. doi:10.1111/his.13975
   PubMed Web of Science ®Google Scholar
• Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P. Cancer of the esophageal and esophagogastric junction: an eighth edition staging primer. J Thorac Oncol. 2017;12(1):36–42. doi:10.1016/j.jtho.2016.10.016
   PubMed Web of Science ®Google Scholar
• Zhu Y, Ramos da Silva S, He M, et al. An oncogenic virus promotes cell survival and cellular transformation by suppressing glycolysis. PLoS Pathog. 2016;12(5):e1005648. doi:10.1371/journal.ppat.1005648
   PubMed Web of Science ®Google Scholar
• Gruffaz M, Vasan K, Tan B, Ramos da Silva S, Gao SJ. TLR4-mediated inflammation promotes KSHV-induced cellular transformation and tumorigenesis by activating the STAT3 pathway. Cancer Res. 2017;77(24):7094–7108. doi:10.1158/0008-5472.Can-17-2321
   PubMed Web of Science ®Google Scholar
• Warde-Farley D, Donaldson SL, Comes O, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(suppl_2):W214–W220. doi:10.1093/nar/gkq537
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218. doi:10.1186/s13059-016-1070-5
   PubMed Web of Science ®Google Scholar
• Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–w514. doi:10.1093/nar/gkaa407
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4(1):2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Fu J, Li K, Zhang W, et al. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 2020;12(1):21. doi:10.1186/s13073-020-0721-z
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar
• Sturm G, Finotello F, Petitprez F, et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics. 2019;35(14):i436–i445. doi:10.1093/bioinformatics/btz363
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. doi:10.1186/s13059-017-1349-1
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262. doi:10.1016/j.celrep.2016.12.019
   PubMed Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor–immune system interactions. Bioinformatics. 2019;35(20):4200–4202. doi:10.1093/bioinformatics/btz210
   PubMed Web of Science ®Google Scholar
• Su R, Shereen MA, Zeng X, et al. The TLR3/IRF1/Type III IFN axis facilitates antiviral responses against enterovirus infections in the intestine. mBio. 2020;11:6. doi:10.1128/mBio.02540-20
   Web of Science ®Google Scholar
• Li A, Wu H, Tian Q, Zhang Y, Zhang Z, Zhang X. Methylation regulation of TLR3 on immune parameters in lung adenocarcinoma. Front Oncol. 2021;11:620200. doi:10.3389/fonc.2021.620200
   PubMed Web of Science ®Google Scholar
• Chew V, Abastado JP. Immunomodulation of the tumor microenvironment by Toll-like receptor-3 (TLR3) ligands. Oncoimmunology. 2013;2(4):e23493. doi:10.4161/onci.23493
   PubMed Web of Science ®Google Scholar
• Helminen O, Huhta H, Lehenkari PP, Saarnio J, Karttunen TJ, Kauppila JH. Nucleic acid-sensing toll-like receptors 3, 7 and 8 in esophageal epithelium, Barrett’s esophagus, dysplasia and adenocarcinoma. Oncoimmunology. 2016;5(5):e1127495. doi:10.1080/2162402x.2015.1127495
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41. doi:10.1016/j.immuni.2019.06.025
   PubMed Web of Science ®Google Scholar
• Lim DM, Wang ML. Toll-like receptor 3 signaling enables human esophageal epithelial cells to sense endogenous danger signals released by necrotic cells. Am J Physiol Gastrointest Liver Physiol. 2011;301(1):G91–99. doi:10.1152/ajpgi.00471.2010
   PubMed Web of Science ®Google Scholar
• Alkurdi L, Virard F, Vanbervliet B, et al. Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis. Cell Death Dis. 2018;9(9):874. doi:10.1038/s41419-018-0850-0
   PubMed Web of Science ®Google Scholar
• Bianchi F, Alexiadis S, Camisaschi C, et al. TLR3 expression induces apoptosis in human non-small-cell lung cancer. Int J Mol Sci. 2020;21:4. doi:10.3390/ijms21041440
   Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566. doi:10.1158/0008-5472.Can-18-3962
   PubMed Web of Science ®Google Scholar
• Takeda Y, Kataoka K, Yamagishi J, Ogawa S, Seya T, Matsumoto M. A TLR3-specific adjuvant relieves innate resistance to PD-L1 blockade without cytokine toxicity in tumor vaccine immunotherapy. Cell Rep. 2017;19(9):1874–1887. doi:10.1016/j.celrep.2017.05.015
   PubMed Web of Science ®Google Scholar
• Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Trial watch: TLR3 agonists in cancer therapy. Oncoimmunology. 2020;9(1):1771143. doi:10.1080/2162402x.2020.1771143
   PubMed Web of Science ®Google Scholar
• Seya T, Takeda Y, Matsumoto MA. Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy. Adv Drug Deliv Rev. 2019;147:37–43. doi:10.1016/j.addr.2019.07.008
   PubMed Web of Science ®Google Scholar
• Belgiovine C, D’Incalci M, Allavena P, Frapolli R. Tumor-associated macrophages and anti-tumor therapies: complex links. Cell Mol Life Sci. 2016;73(13):2411–2424. doi:10.1007/s00018-016-2166-5
   PubMed Web of Science ®Google Scholar
• Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv Cancer Res. 2015;128:95–139. doi:10.1016/bs.acr.2015.04.002
   PubMed Web of Science ®Google Scholar